Compare stocks

BLTE vs CMPX

Belite Bio, Inc American Depositary Shares and Compass Therapeutics, Inc. Common Stock

Compare the businesses

Belite Bio, Inc American Depositary Shares

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Open BLTE dashboard ↗

Compass Therapeutics, Inc. Common Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Open CMPX dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗